

# Portable Amperometric Biosensor Improved with Enzyme-based Ternary Nanocomposites for Detecting Prostate Cancer Biomarkers

Mitchell Moreno\*

Department of Electrical Engineering, List of Colleges and Universities in Virginia, Virginia, USA

## Introduction

The development of innovative biosensing technologies for the early detection of prostate cancer has garnered significant attention in recent years. Among these technologies, portable Amperometric biosensors have shown immense promise due to their sensitivity, specificity, portability, and rapid response times. The integration of enzyme-based ternary nanocomposites into these biosensors represents a groundbreaking advancement, offering enhanced detection capabilities for prostate cancer biomarkers. This discussion explores the principles, design, and advantages of these biosensors, along with their potential for revolutionizing prostate cancer diagnostics. Prostate-specific antigen is the most widely used biomarker for detecting prostate cancer. Elevated PSA levels in blood serum are often indicative of the presence or progression of the disease. While conventional methods such as enzyme-linked immunosorbent assays are effective for PSA detection, they are often time-consuming, expensive, and require specialized laboratory equipment. In contrast, Amperometric biosensors provide a faster, cost-effective, and portable alternative, enabling point-of-care testing and real-time monitoring. The integration of enzyme-based ternary nanocomposites into the biosensor architecture significantly enhances its performance, addressing key challenges in biomarker detection.

Ternary nanocomposites, comprising three distinct components with complementary properties, play a pivotal role in improving the sensitivity and functionality of Amperometric biosensors. These materials combine the advantages of high surface area, excellent conductivity, and biocompatibility, providing an ideal environment for immobilizing enzymes and enhancing electron transfer. A typical ternary nanocomposite for prostate cancer detection may include metallic nanoparticles, conductive polymers, and carbon-based nanomaterials. This combination offers synergistic effects, amplifying the electrochemical signal generated during biomarker detection.

## Description

The construction of the biosensor begins with the fabrication of the electrode, often using a conductive substrate such as glassy carbon, gold, or platinum. The ternary nanocomposite is then deposited onto the electrode surface, creating a robust platform for enzyme immobilization. Techniques such as drop-casting, spin-coating, or electrodeposition are employed to ensure uniform and stable nanocomposite layers. The enzyme is subsequently immobilized onto the nanocomposite through covalent bonding, adsorption, or entrapment methods, depending on the desired stability and activity [1].

Despite the significant advancements, challenges remain in the development and commercialization of these biosensors. One major challenge is the scalability and reproducibility of the fabrication process. Ensuring

**\*Address for Correspondence:** Mitchell Moreno, Department of Electrical Engineering, List of Colleges and Universities in Virginia, Virginia, USA; E-mail: mitchelloreno@dee.edu

**Copyright:** © 2024 Moreno M. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

**Received:** 02 December, 2024, Manuscript No. jbsbe-25-156909; **Editor Assigned:** 04 December, 2024, PreQC No. P-156909; **Reviewed:** 18 December, 2024, QC No. Q-156909; **Revised:** 23 December, 2024, Manuscript No. R-156909; **Published:** 30 December, 2024, DOI:10.37421/2155-6210.2024.15.478

consistent performance across multiple sensors is critical for widespread adoption. Additionally, the integration of biosensors with portable and user-friendly readout devices requires further optimization to ensure seamless operation. Addressing these challenges will be essential for translating this technology from the laboratory to clinical settings. Regulatory approval and validation are other critical aspects that need to be addressed. Rigorous testing and standardization are required to demonstrate the safety, accuracy, and reliability of Amperometric biosensors for prostate cancer detection. Collaboration between researchers, clinicians, and regulatory bodies will be essential to accelerate the adoption of this technology in routine clinical practice.

The future prospects of portable Amperometric biosensors are highly promising. Advances in nanomaterials, enzyme engineering, and microfabrication techniques are expected to further enhance their performance and utility. For instance, the use of nanostructured materials with hierarchical architectures could provide even greater surface areas and improved electron transfer capabilities. Similarly, engineering enzymes with enhanced stability and catalytic efficiency could further improve the sensitivity and robustness of the biosensors. Moreover, the integration of biosensors with wireless communication technologies and cloud-based data analytics holds immense potential for remote monitoring and telemedicine applications. By enabling real-time data transmission and analysis, these systems could facilitate personalized healthcare and early intervention for prostate cancer patients. The combination of biosensors with artificial intelligence and machine learning algorithms could also enable predictive analytics, providing valuable insights into disease progression and treatment response [2]

## Conclusion

Portable Amperometric biosensors enhanced with enzyme-based ternary nanocomposites represent a transformative approach to prostate cancer diagnostics. By leveraging the unique properties of nanocomposites and the catalytic activity of enzymes, these biosensors offer unparalleled sensitivity, selectivity, and portability. While challenges remain in terms of scalability, validation, and integration, ongoing advancements in technology and interdisciplinary collaboration are poised to overcome these barriers. This innovative approach has the potential to revolutionize prostate cancer detection and monitoring, ultimately improving patient outcomes and reducing the burden on healthcare systems.

## References

1. Bray Freddie, Mathieu Laversanne, Hyuna Sung and Jacques Ferlay, et al. "Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries." *CA Cancer J Clin* 74 (2024): 229-263.
2. Kim Jae Hyun, Young Joon Suh, Dongsung Park and Hyoju Yim, et al. "Technological advances in electrochemical biosensors for the detection of disease biomarkers." *Biomed Eng Lett* 11 (2021): 309-334.

**How to cite this article:** Moreno, Mitchell. "Portable Amperometric Biosensor Improved with Enzyme-based Ternary Nanocomposites for Detecting Prostate Cancer Biomarkers." *J Biosens Bioelectron* 15 (2024): 478.